FSHR and hypogonadotropic hypogonadism: The AMPLITUDE panel supported that unexpected hormonal levels (stagnant E2 or LH <1.2 ng/ml), hypogonadotropic hypogonadism, stagnant follicular growth, advanced age and suspected FSH receptor polymorphism, are additional indications for LH/hCG activity supplementation.